External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Stock investment endeavours to deliver consistent outperformance in the long term by making a diversified investment of ‘Winners’.</li><li>Axis Intellect (AI) Score based Investment Approach for Stock Selection applies unique approach to deliver alpha by applying equal exposure to ‘Core’ and ‘Satellite’ factors.</li><li>What are ‘Core’ Factors’: Low Volatility, Value, Growth, Quality, Momentum (Equal weighted 50% exposure) What are ‘Satellite’ Factors: Factors that have historically done well in the predicted regime modelling (Remaining 50% exposure)</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Stock investment endeavours to deliver consistent outperformance in the long term by making a diversified investment of ‘Winners’.Axis Intellect (AI) Score based Investment Approach for Stock Selection applies unique approach to deliver alpha by applying equal exposure to ‘Core’ and ‘Satellite’ factors.What are ‘Core’ Factors’: Low Volatility, Value, Growth, Quality, Momentum (Equal weighted 50% exposure) What are ‘Satellite’ Factors: Factors that have historically done well in the predicted regime modelling (Remaining 50% exposure)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>Q4 FY26 earnings reveal India's four pharma giants pivoting hard to chronic therapies, racing to capture post-patent GLP-1 market, and completing two of the sector's largest-ever acquisitions within six weeks.</li>
<li>Domestic Indian market is now fastest-growing engine, no longer just a low-cost manufacturing base, while US tariff uncertainty and Revlimid expiries reinforce structural shift toward emerging markets and proprietary molecules.</li>
<li>FY27 will separate execution from ambition: SunPharma must revive near-stagnant Organon acquisition , Torrent must manage 2.3x leverage, Cipla must defend EBITDA guidance ,Zydus must prove its multi-engine model efficiently.  </li>
</ul>


Q4 FY26 earnings reveal India's four pharma giants pivoting hard to chronic therapies, racing to capture post-patent GLP-1 market, and completing two of the sector's largest-ever acquisitions within six weeks.
Domestic Indian market is now fastest-growing engine, no longer just a low-cost manufacturing base, while US tariff uncertainty and Revlimid expiries reinforce structural shift toward emerging markets and proprietary molecules.
FY27 will separate execution from ambition: SunPharma must revive near-stagnant Organon acquisition , Torrent must manage 2.3x leverage, Cipla must defend EBITDA guidance ,Zydus must prove its multi-engine model efficiently.  


Why India's Pharma Giants Are Betting on Chronic Business?

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Equity Bottom-Up

Torrent Pharmaceuticals / Equity Bottom-Up

<ul>
<li>Torrent Pharmaceuticals has captured roughly 38% of India's nascent generic semaglutide market in April 2026, generating approximately INR17 crore in monthly sales within weeks of patent expiry.</li>
<li>India's anti-obesity GLP-1 market is worth INR 1,600 crore today and is forecast to reach INR 4,500-5,000 crore by 2030. Early share in a winner-takes-most therapeutic is disproportionately durable.</li>
<li>Torrent's format breadth and chronic-therapy distribution infrastructure are structural moats that one-format rivals cannot replicate quickly. </li>
</ul>


Torrent Pharmaceuticals has captured roughly 38% of India's nascent generic semaglutide market in April 2026, generating approximately INR17 crore in monthly sales within weeks of patent expiry.
India's anti-obesity GLP-1 market is worth INR 1,600 crore today and is forecast to reach INR 4,500-5,000 crore by 2030. Early share in a winner-takes-most therapeutic is disproportionately durable.
Torrent's format breadth and chronic-therapy distribution infrastructure are structural moats that one-format rivals cannot replicate quickly. 


How Torrent Won the Generic Semaglutide Race?

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Hengrui Pharmaceuticals entered license agreements with BMS to advance 13 early-stage programs in oncology, hematology, and immunology. Sino Biopharmaceutical entered exclusive strategic collaboration with GlaxoSmithKline for Hepatitis B drug bepirovisen.</li>
<li>BeOne received FDA approval for Beqalzi for the treatment of mantle cell lymphoma. Otsuka’s subsidiary, Taiho Pharmaceutical secured FDA approval for Inqovi plus venetoclax for newly diagnosed acute myeloid leukemia.</li>
<li>Celltrion has acquired Gifrer, a 114-year-old local healthcare company in France. Bora Pharmaceuticals will acquire GMP manufacturing operations, including the CDMO business, of MacroGenics for $122.5M.</li>
</ul>


Hengrui Pharmaceuticals entered license agreements with BMS to advance 13 early-stage programs in oncology, hematology, and immunology. Sino Biopharmaceutical entered exclusive strategic collaboration with GlaxoSmithKline for Hepatitis B drug bepirovisen.
BeOne received FDA approval for Beqalzi for the treatment of mantle cell lymphoma. Otsuka’s subsidiary, Taiho Pharmaceutical secured FDA approval for Inqovi plus venetoclax for newly diagnosed acute myeloid leukemia.
Celltrion has acquired Gifrer, a 114-year-old local healthcare company in France. Bora Pharmaceuticals will acquire GMP manufacturing operations, including the CDMO business, of MacroGenics for $122.5M.


APAC Healthcare Weekly (May 17) – Hengrui, Sino Bio, BeOne, Otsuka, Celltrion, Bora Pharmaceuticals

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<ul>
<li>A group of shareholders raised around US$530m in <a href="https://www.smartkarma.com/entities/mankind-pharma-ltd" target="_blank" data-smartkarma-citation="entities:36389:1" rel="noopener">Mankind Pharma</a>(MP) IPO in May 2023. The pre-IPO shareholders will be released from their lockup soon.</li>
<li>MP is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.</li>
<li>In this note, we will talk about the lock-up dynamics and recent updates.</li>
</ul>


A group of shareholders raised around US$530m in Mankind Pharma(MP) IPO in May 2023. The pre-IPO shareholders will be released from their lockup soon.
MP is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
In this note, we will talk about the lock-up dynamics and recent updates.


Mankind Pharma Lock-Up - A US$1.1bn+ Lockup Release

India

Torrent Pharmaceuticals Ltd. manufactures bulk drugs and pharmaceutical formulations. The Company's formulations include cardio-vascular, psychotropic and anti-biotic drugs while its bulk drugs include atenolol, ciprofloxacin and norfloxacin. Torrent Pharmaceuticals has wholly owned subsidiaries in several regulated and less regulated international markets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Torrent Pharmaceuticals (TRP IN)

Axis Intellect - Aggressive

Stock investment endeavours to deliver consistent outperformance in the long term by making a diversified investment of ‘Winners’.

Axis Direct

Why India's Pharma Giants Are Betting on Chronic Business?

India's top pharma companies shift focus to chronic therapies, target post-patent GLP-1 market, and make major acquisitions, with FY27 set to test...

Sudarshan Bhandari

How Torrent Won the Generic Semaglutide Race?

Torrent Pharmaceuticals dominates India's generic semaglutide market, capitalizing on early share in a growing anti-obesity market set to reach...

Nimish Maheshwari

APAC Healthcare Weekly (May 17) – Hengrui, Sino Bio, BeOne, Otsuka, Celltrion, Bora Pharmaceuticals

Hengrui stuck licensing agreement with BMS. Sino Bio enters exclusive collaboration with GSK. BeOne got FDA approval for new drug. Bora will...

Tina Banerjee

Mankind Pharma Lock-Up - A US$1.1bn+ Lockup Release

The two pre-IPO investors have launched a block to sell around US$591m worth of Mankind Pharma shares. Since the lockup on the shares expired not...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Axis Intellect - Aggressive

Stock investment endeavours to deliver consistent outperformance in the long term by making a diversified investment of ‘Winners’.

Axis Direct

Why India's Pharma Giants Are Betting on Chronic Business?

​India's top pharma companies shift focus to chronic therapies, target post-patent GLP-1 market, and make major acquisitions, with FY27 set to test...

Sudarshan Bhandari

How Torrent Won the Generic Semaglutide Race?

​Torrent Pharmaceuticals dominates India's generic semaglutide market, capitalizing on early share in a growing anti-obesity market set to reach...

Nimish Maheshwari

APAC Healthcare Weekly (May 17) – Hengrui, Sino Bio, BeOne, Otsuka, Celltrion, Bora Pharmaceuticals

Hengrui stuck licensing agreement with BMS. Sino Bio enters exclusive collaboration with GSK. BeOne got FDA approval for new drug. Bora will...

Tina Banerjee

Mankind Pharma Lock-Up - A US$1.1bn+ Lockup Release

The two pre-IPO investors have launched a block to sell around US$591m worth of Mankind Pharma shares. Since the lockup on the shares expired not...

Sumeet Singh

India's top pharma companies shift focus to chronic therapies, target post-patent GLP-1 market, and make major acquisitions, with FY27 set to test...

Torrent Pharmaceuticals dominates India's generic semaglutide market, capitalizing on early share in a growing anti-obesity market set to reach...